LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF THE GLOBAL ANTI-INFLAMMATORY DRUGS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 LIST OF MAJOR INFLAMMATORY DISEASES
EXHIBIT 4 IMPACT OF PROMISING INVESTIGATIONAL DRUGS IN CLINICAL TRIAL PIPELINES
EXHIBIT 5 IMPACT OF SURGE IN AVAILABILITY OF APPROVED BIOSIMILARS TO TREAT INFLAMMATORY DISEASES
EXHIBIT 6 IMPACT OF RISE IN COMMERCIALIZATION OF ANTI-INFLAMMATORY DRUGS
EXHIBIT 7 IMPACT OF PREFERENCE FOR ANTI-INFLAMMATORY DRUGS AMONG PATIENT GROUPS
EXHIBIT 8 IMPACT OF RISING PREVALENCE OF INFLAMMATORY DISEASES
EXHIBIT 9 BURDEN STATISTICS FOR DIFFERENT AUTOIMMUNE DISEASES
EXHIBIT 10 COPD DISEASE BURDEN STATISTICS
EXHIBIT 11 IMPACT OF GROWING USE OF BIOLOGICS TO TREAT INFLAMMATORY DISEASES
EXHIBIT 12 IMPACT OF PATENT EXPIRATION OF ANTI-INFLAMMATORY DRUGS
EXHIBIT 13 IMPACT OF SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS
EXHIBIT 14 COMMON SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS
EXHIBIT 15 ADVERSE EFFECTS OF ANTI-INFLAMMATORY DRUGS
EXHIBIT 16 IMPACT OF PRODUCT RECALLS DUE TO STRINGENT REGULATORY GUIDELINES
EXHIBIT 17 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 18 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY
EXHIBIT 19 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS
EXHIBIT 20 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION
EXHIBIT 21 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION
EXHIBIT 22 FIVE FORCES ANALYSIS 2021
EXHIBIT 23 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
EXHIBIT 24 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS
EXHIBIT 25 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS: INCREMENTAL GROWTH
EXHIBIT 26 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS: ABSOLUTE GROWTH
EXHIBIT 27 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021–2027 ($ BILLION)
EXHIBIT 29 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 30 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021–2027 ($ BILLION)
EXHIBIT 31 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 32 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021–2027 ($ BILLION)
EXHIBIT 33 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021–2027 ($ BILLION)
EXHIBIT 35 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 36 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION
EXHIBIT 37 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION: INCREMENTAL GROWTH
EXHIBIT 38 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021–2027 ($ BILLION)
EXHIBIT 40 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021–2027 ($BILLION)
EXHIBIT 42 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021–2027 ($ BILLION)
EXHIBIT 44 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 45 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION
EXHIBIT 46 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION: INCREMENTAL GROWTH
EXHIBIT 47 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION: ABSOLUTE GROWTH
EXHIBIT 48 TYPES OF PARENTERAL ROUTES OF ADMINISTRATION
EXHIBIT 49 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 51 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 MAJOR ORAL ANTI-INFLAMMATORY DRUGS
EXHIBIT 53 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 54 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 56 GLOBAL INHALATION ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 GLOBAL INHALATION ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 58 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 59 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY
EXHIBIT 60 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: KEY COUNTRIES ($ BILLION)
EXHIBIT 61 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 62 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 63 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 64 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 65 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 66 INCREMENTAL GROWTH BY DRUG CLASS 2021 & 2027
EXHIBIT 67 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 68 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 69 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 70 US ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 71 CANADA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 72 EUROPE ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
EXHIBIT 73 EUROPE ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 74 EUROPE ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 75 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
EXHIBIT 76 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
EXHIBIT 77 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 78 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 79 GERMANY ANTI-INFLAMMATORY DRUGS MARKET 2020–2027 ($BILLION)
EXHIBIT 80 UK ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 81 MORTALITY PERCENTAGE ASSOCIATED WITH CHRONIC INFLAMMATORY DISEASES
EXHIBIT 82 FRANCE ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 83 ITALY ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 84 SPAIN ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 85 APAC ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
EXHIBIT 86 APAC ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 87 APAC ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 88 INCREMENTAL GROWTH BY DRUG CLASS 2021 & 2027
EXHIBIT 89 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
EXHIBIT 90 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 91 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 92 CHINA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 93 JAPAN ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 94 INDIA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 95 AUSTRALIA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 96 SOUTH KOREA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 97 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
EXHIBIT 98 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 99 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 100 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
EXHIBIT 101 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 102 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 103 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 104 BRAZIL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 105 MEXICO ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 106 ARGENTINA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 107 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
EXHIBIT 108 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 109 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)
EXHIBIT 110 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
EXHIBIT 111 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
EXHIBIT 112 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 113 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 114 TURKEY ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 115 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 116 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)
EXHIBIT 117 ABBVIE: REVENUE 2018–2020 ($ BILLION)
EXHIBIT 118 ABBVIE: R&D EXPENDITURE 2018–2020 ($ BILLION)
EXHIBIT 119 ABBVIE: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)
EXHIBIT 120 AMGEN: TOTAL REVENUE 2018–2020 ($ MILLION)
EXHIBIT 121 AMGEN: R&D EXPENDITURE 2018–2020 ($ MILLION)
EXHIBIT 122 BIOGEN: REVENUE 2018–2020 ($ BILLION)
EXHIBIT 123 BIOGEN: REVENUE BY PRODUCT CATEGORIES 2018–2020 ($ MILLION)
EXHIBIT 124 BIOGEN: R&D EXPENDITURE 2018–2020 ($ MILLION)
EXHIBIT 125 BRISTOL MYERS SQUIBB: TOTAL REVENUE 2018–2020 ($ MILLION)
EXHIBIT 126 BRISTOL MYERS SQUIBB: R&D EXPENDITURE 2018–2020 ($ MILLION)
EXHIBIT 127 BRISTOL MYERS SQUIBB: REVENUE BY GEOGRAPHIC REGION 2020 ($ MILLION)
EXHIBIT 128 ELI LILLY & COMPANY: REVENUE 2018–2020 ($ BILLION)
EXHIBIT 129 ELI LILLY & COMPANY: RESEARCH & DEVELOPMENT 2018–2020 ($ BILLION)
EXHIBIT 130 ELI LILLY & COMPANY: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)
EXHIBIT 131 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2019–2021 ($ BILLION)
EXHIBIT 132 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2019–2021 ($ BILLION)
EXHIBIT 133 GLAXOSMITHKLINE: REVENUE 2018–2020 ($ BILLION)
EXHIBIT 134 GLAXOSMITHKLINE: REVENUE BY BUSINESS SEGMENTS 2018–2020 ($ BILLION)
EXHIBIT 135 GLAXOSMITHKLINE: R& D EXPENDITURE 2018–2020 ($ BILLION)
EXHIBIT 136 GLAXOSMITHKLINE: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)
EXHIBIT 137 JOHNSON & JOHNSON: REVENUE 2018–2020 ($ BILLION)
EXHIBIT 138 MERCK & CO: REVENUE 2018–2020 ($ BILLION)
EXHIBIT 139 MERCK & CO: REVENUE BY SEGMENTS 2018–2020 ($ BILLION)
EXHIBIT 140 MERCK & CO: R&D EXPENDITURE 2018–2020 ($ BILLION)
EXHIBIT 141 NOVARTIS: TOTAL REVENUE 2018–2020 ($ MILLION)
EXHIBIT 142 NOVARTIS: R&D EXPENDITURE 2018-2020 ($ MILLION)
EXHIBIT 143 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2019–2020 ($ MILLION)
EXHIBIT 144 NOVARTIS: REVENUE BY GEOGRAPHY 2020 ($ MILLION)
EXHIBIT 145 PFIZER: REVENUE 2018–2020 ($ BILLION)
EXHIBIT 146 PFIZER: R&D EXPENDITURE 2018–2020 ($ BILLION)
EXHIBIT 147 PFIZER: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)
EXHIBIT 148 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY 2021–2027 ($ BILLION)
EXHIBIT 149 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 150 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 151 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 152 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 153 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 154 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 155 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 156 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 157 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 158 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 159 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 160 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 161 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 162 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 163 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 164 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 165 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 166 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 167 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 168 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)
EXHIBIT 169 GLOBAL INHALATIONAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
EXHIBIT 170 GLOBAL INHALATIONAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 MAJOR PRODUCTS IN THE MANAGEMENT OF INFLAMMATORY DISEASES
TABLE 4 LIST OF MAJOR INVESTIGATIONAL THERAPIES FOR INFLAMMATORY DISEASES
TABLE 5 COST-EFFECTIVENESS OF BIOSIMILARS COMPARED WITH ORIGINATOR BIOLOGICS TO TREAT CHRONIC INFLAMMATORY CONDITIONS
TABLE 6 LIST OF POTENTIAL & APPROVED BIOSIMILARS FOR INFLAMMATORY DISEASES
TABLE 7 LIST OF RECENTLY APPROVED ANTI-INFLAMMATORY DRUGS
TABLE 8 TOP GLOBAL OTC ANTI-INFLAMMATORY DRUG BRANDS
TABLE 9 ANTI-INFLAMMATORY OFF-PATENT PRODUCTS
TABLE 10 PRODUCTS RECALLS IN THE GLOBAL ANTI-INFLAMMATORY DRUGS MARKET
TABLE 11 LIST OF MAJOR BIOLOGICS & BIOSIMILARS APPROVED FOR INFLAMMATORY DISEASES
TABLE 12 MAJOR AVAILABLE PRESCRIPTION NSAIDS
TABLE 13 COMMON EXAMPLES OF PARENTERAL ANTI-INFLAMMATORY DRUGS
TABLE 14 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 15 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 16 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY INDICATION 2021–2027 ($ BILLION)
TABLE 17 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY INDICATION 2021–2027 (%)
TABLE 18 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 19 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 20 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 21 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 22 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 23 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 24 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 25 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 26 APPROVED ANTI-INFLAMMATORY DRUGS IN GERMANY
TABLE 27 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 28 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 29 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 30 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 31 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 32 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 33 NMPA-APPROVED ANTI-INFLAMMATORY BIOSIMILARS 2019
TABLE 34 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 35 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 36 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 37 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 38 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 39 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 40 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 41 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 42 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 43 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 44 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 45 ABBVIE: MAJOR PRODUCT OFFERINGS
TABLE 46 AMGEN: MAJOR PRODUCT OFFERINGS
TABLE 47 BIOGEN: MAJOR PRODUCT OFFERINGS
TABLE 48 BRISTOL MYERS SQUIBB: MAJOR PRODUCT OFFERINGS
TABLE 49 ELI LILLY & COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 50 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 51 GLAXOSMITHKLINE: MAJOR PRODUCT OFFERINGS
TABLE 52 JOHNSON & JOHNSON: MAJOR PRODUCT OFFERINGS
TABLE 53 MERCK & CO: MAJOR PRODUCT OFFERINGS
TABLE 54 NOVARTIS: MAJOR PRODUCT OFFERINGS
TABLE 55 PFIZER: MAJOR PRODUCT OFFERINGS
TABLE 56 ACTIZA PHARMACEUTICAL: MAJOR PRODUCT OFFERINGS
TABLE 57 ALLERGAN: MAJOR PRODUCT OFFERINGS
TABLE 58 ANTIBE THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 59 AURINIA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 60 ASTRAZENECA: MAJOR PRODUCT OFFERINGS
TABLE 61 AUROBINDO PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 62 BAYER: MAJOR PRODUCT OFFERINGS
TABLE 63 BIO-THERA SOLUTIONS: MAJOR PRODUCT OFFERINGS
TABLE 64 CADILA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 65 CIPLA: MAJOR PRODUCT OFFERINGS
TABLE 66 CELLTRION: MAJOR PRODUCT OFFERINGS
TABLE 67 CENTURION REMEDIES: MAJOR PRODUCT OFFERINGS
TABLE 68 DR. REDDY’S LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 69 EISAI: MAJOR PRODUCT OFFERINGS
TABLE 70 GILEAD SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 71 GLENMARK PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 72 LUPIN: MAJOR PRODUCT OFFERINGS
TABLE 73 MEDICO REMEDIES: MAJOR PRODUCT OFFERINGS
TABLE 74 REGENERON PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 75 SAMSUNG BIOEPIS: MAJOR PRODUCT OFFERINGS
TABLE 76 SANOFI: MAJOR PRODUCT OFFERINGS
TABLE 77 SUN PHARMACEUTICAL INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 78 SWEDISH ORPHAN BIOVITRUM: MAJOR PRODUCT OFFERINGS
TABLE 79 UCB: MAJOR PRODUCT OFFERINGS
TABLE 80 FUJIFILM KYOWA KIRIN BIOLOGICS: MAJOR PRODUCT OFFERINGS
TABLE 81 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 82 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 83 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 84 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 85 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 86 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 87 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 88 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 89 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 90 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 91 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)
TABLE 92 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)
TABLE 93 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 94 GLOBAL AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 95 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 96 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 97 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 98 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 99 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 100 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 101 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 102 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 103 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 104 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)
TABLE 105 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 106 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 107 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 108 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 109 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 110 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 111 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 112 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 113 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 114 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 115 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)
TABLE 116 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 117 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY 2021–2027 (%)